carteolol has been researched along with Chronic Primary Open Angle Glaucoma in 39 studies
Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the 24-h efficacy and safety of fixed combination carteolol/latanoprost (LCFC) and timolol/latanoprost (LTFC) in patients with primary open-angle glaucoma and ocular hypertension." | 9.41 | Comparison of the 24-h efficacy and safety of fixed combination carteolol/latanoprost and timolol/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study. ( Aihara, M; Kishimoto, N; Kizaki, J; Saito, Y; Shibasaki, Y; Wada, Y, 2021) |
| "To assess the comparative efficacy of latanoprostene bunod (LBN), a novel prostaglandin analogue (PGA), to other medications for open-angle glaucoma and ocular hypertension on lowering intraocular pressure (IOP)." | 9.22 | Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. ( Barbeau, M; Beauchemin, C; Cui, AX; Harasymowycz, P; Jobin-Gervais, K; Lachaine, J; Mathurin, K; Royer, C, 2022) |
| "To assess the intraocular pressure (IOP)-lowering effects and safety of a carteolol/latanoprost fixed combination drug (OPC-1085EL) vs latanoprost (Study 1) and carteolol (Study 2) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH)." | 9.22 | Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension. ( Ikegami, T; Ishikawa, Y; Kikuchi, S; Yamamoto, T, 2016) |
| "The effects of switching from topical beta-blockers (beta) to latanoprost (LA) on intraocular pressure (IOP) and IOP-reduction rate (IOP-RR) in patients with normal-tension glaucoma (NTG) were investigated." | 9.13 | Effects of switching from topical beta-blockers to latanoprost on intraocular pressure in patients with normal-tension glaucoma. ( Ikeda, Y; Ishibashi, T; Kinoshita, S; Mori, K; Nakajima, N; Naruse, S, 2008) |
| "To compare the ocular hypotensive activity and safety profile of long-acting 1% carteolol hydrochloride eye drops (long-acting formulation) to those of 1% carteolol hydrochloride eye drops(currently prescribed drug) for reduction of intraocular pressure." | 9.12 | [Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product]. ( Yamamoto, T, 2007) |
| "Carteolol appears to be neutral in its effect on serum lipid levels, whereas timolol maleate adversely affects the HDL and TC/HDL ratio in women age 60 years and older with ocular hypertension or primary open-angle glaucoma." | 9.09 | Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. ( Apostolaros, M; Dubiner, HB; Hudgins, AC; Katz, LJ; Laibovitz, RA; Mundorf, TK; Nussbaum, L; Sall, KN; Shulman, DG; Siegel, LI; Singh, K; Stewart, WC, 1999) |
| "3% metipranolol on intraocular pressure (IOP) in 45 patients with primary open-angle glaucoma (POAG) and ocular hypertension." | 9.09 | Comparison of the effects of 0.5% timolol maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects. ( Karaküçük, S; Mirza, GE; Temel, E, 2000) |
| "Efficacy and safety of ready to use eye drops 2% carteolol-2% pilocarpine combination proved to be comparable to that of eye drops to be reconstituted in the treatment of ocular hypertension poorly controlled by beta-blocker eye drops alone." | 9.08 | [Efficacy and tolerability of 2 presentations of eyedrops combining carteolol 2% and pilocarpine 2% in primary open-angle glaucoma and simple ocular hypertension]. ( Charlin, JF; Cohn, H; Dascotte, JC; George, JL; Lesure, P; Massin, G; Massin, M; Maurin, JF; Renard, JP; Sirbat, D, 1995) |
| "Timolol causes significantly lower mean heart rate during the nighttime and more nocturnal bradycardia than carteolol does in patients with ocular hypertension and primary open-angle glaucoma." | 9.08 | Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group. ( Cohen, JS; Netland, PA; Nussbaum, LL; Stewart, WC; Weiss, HS, 1997) |
| "In patients with normal-tension glaucoma (NTG), topical dorzolamide might enhance the vessel density (VD), topical carteolol decreased the VD in the inferior-temporal peripapillary retina, whereas topical brimonidine did not change the VD." | 8.02 | Optical Coherence Tomography Angiography Vessel Density Changes in Normal-tension Glaucoma Treated With Carteolol, Brimonidine, or Dorzolamide. ( Chen, LC; Chuang, LH; Huang, SM; Lin, YH; Su, WW, 2021) |
| "The purpose of the study was to evaluate influence of betaxolol, brimonidine and carteolol in the progression of the visual field defects during time at patients with normotensive glaucoma (NTG)." | 7.96 | Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma. ( Fůs, M; Lešták, J; Marešová, K; Weissová, I, 2020) |
| "We prospectively investigated the efficacy and safety of switching from concomitant latanoprost and carteolol hydrochloride (CH) to a latanoprost/carteolol fixed combination (LCFC) in patients with primary open-angle glaucoma or ocular hypertension." | 7.88 | Short-term Efficacy and Safety of a Latanoprost/Carteolol Fixed Combination Switched From Concomitant Therapy to in Patients With Primary Open-angle Glaucoma or Ocular Hypertension. ( Inoue, K; Ishida, K; Iwasa, M; Shiokawa, M; Tomita, G, 2018) |
| "To evaluate the 24-h efficacy and safety of fixed combination carteolol/latanoprost (LCFC) and timolol/latanoprost (LTFC) in patients with primary open-angle glaucoma and ocular hypertension." | 5.41 | Comparison of the 24-h efficacy and safety of fixed combination carteolol/latanoprost and timolol/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study. ( Aihara, M; Kishimoto, N; Kizaki, J; Saito, Y; Shibasaki, Y; Wada, Y, 2021) |
| "To assess the comparative efficacy of latanoprostene bunod (LBN), a novel prostaglandin analogue (PGA), to other medications for open-angle glaucoma and ocular hypertension on lowering intraocular pressure (IOP)." | 5.22 | Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. ( Barbeau, M; Beauchemin, C; Cui, AX; Harasymowycz, P; Jobin-Gervais, K; Lachaine, J; Mathurin, K; Royer, C, 2022) |
| "To assess the intraocular pressure (IOP)-lowering effects and safety of a carteolol/latanoprost fixed combination drug (OPC-1085EL) vs latanoprost (Study 1) and carteolol (Study 2) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH)." | 5.22 | Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension. ( Ikegami, T; Ishikawa, Y; Kikuchi, S; Yamamoto, T, 2016) |
| "The effects of switching from topical beta-blockers (beta) to latanoprost (LA) on intraocular pressure (IOP) and IOP-reduction rate (IOP-RR) in patients with normal-tension glaucoma (NTG) were investigated." | 5.13 | Effects of switching from topical beta-blockers to latanoprost on intraocular pressure in patients with normal-tension glaucoma. ( Ikeda, Y; Ishibashi, T; Kinoshita, S; Mori, K; Nakajima, N; Naruse, S, 2008) |
| "To compare the additive effect of dorzolamide or carteolol to latanoprost on intraocular pressure (IOP) in glaucoma patients." | 5.12 | Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial. ( Maruyama, K; Shirato, S, 2006) |
| "To compare the ocular hypotensive activity and safety profile of long-acting 1% carteolol hydrochloride eye drops (long-acting formulation) to those of 1% carteolol hydrochloride eye drops(currently prescribed drug) for reduction of intraocular pressure." | 5.12 | [Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product]. ( Yamamoto, T, 2007) |
| "In this double-masked, randomised, intra-subject comparative study, 23 patients with bilateral primary open-angle glaucoma or bilateral ocular hypertension received sequentially, according to the randomised order of administration, each of the 2 following treatments: carteolol 2% LA once daily for 2 months and carteolol 2% regular twice daily for 2 months." | 5.11 | Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients. ( Allaire, C; Cochereau, I; Elena, PP; Jaulerry, S; Kovalski, JL; Lablache Combier, M; Renard, P; Siou-Mermet, R; Williamson, W, 2005) |
| "Carteolol appears to be neutral in its effect on serum lipid levels, whereas timolol maleate adversely affects the HDL and TC/HDL ratio in women age 60 years and older with ocular hypertension or primary open-angle glaucoma." | 5.09 | Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. ( Apostolaros, M; Dubiner, HB; Hudgins, AC; Katz, LJ; Laibovitz, RA; Mundorf, TK; Nussbaum, L; Sall, KN; Shulman, DG; Siegel, LI; Singh, K; Stewart, WC, 1999) |
| "These results suggest that topical carteolol hydrochloride may have a more favorable blood lipid profile than topical timolol maleate in postmenopausal black women with POAG or ocular hypertension." | 5.09 | Central nervous system and plasma lipid profiles associated with carteolol and timolol in postmenopausal black women. ( Bartlett, JD; Olivier, M; Pensyl, D; Richardson, T; Whitaker, R; Wilson, MR, 1999) |
| "3% metipranolol on intraocular pressure (IOP) in 45 patients with primary open-angle glaucoma (POAG) and ocular hypertension." | 5.09 | Comparison of the effects of 0.5% timolol maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects. ( Karaküçük, S; Mirza, GE; Temel, E, 2000) |
| "Carteolol is a beta adrenoceptor antagonist used topically to reduce intraocular pressure, typically twice daily." | 5.09 | Ocular hypotensive efficacy and safety of once daily carteolol alginate. ( Allaire, C; Demailly, P; Trinquand, C, 2001) |
| "Efficacy and safety of ready to use eye drops 2% carteolol-2% pilocarpine combination proved to be comparable to that of eye drops to be reconstituted in the treatment of ocular hypertension poorly controlled by beta-blocker eye drops alone." | 5.08 | [Efficacy and tolerability of 2 presentations of eyedrops combining carteolol 2% and pilocarpine 2% in primary open-angle glaucoma and simple ocular hypertension]. ( Charlin, JF; Cohn, H; Dascotte, JC; George, JL; Lesure, P; Massin, G; Massin, M; Maurin, JF; Renard, JP; Sirbat, D, 1995) |
| "Timolol causes significantly lower mean heart rate during the nighttime and more nocturnal bradycardia than carteolol does in patients with ocular hypertension and primary open-angle glaucoma." | 5.08 | Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group. ( Cohen, JS; Netland, PA; Nussbaum, LL; Stewart, WC; Weiss, HS, 1997) |
| "5% levobunolol and 2% carteolol were compared in 59 patients with open-angle glaucoma or ocular hypertension." | 5.07 | A comparison of the ocular hypotensive efficacy and systemic safety of 0.5% levobunolol and 2% carteolol. ( Behrens-Baumann, W; Kimmich, F; Lue, J; Walt, JG, 1994) |
| " Its effect on intraocular pressure and heart rate was tested in a comparison with timolol maleate, as was subjective tolerance of it, in 28 eyes (14 subjects) with either ocular hypertension or simple chronic open-angle glaucoma." | 5.06 | [Tolerance and pharmacologic effectiveness of antiglaucoma eyedrops]. ( Flury, H; Martenet, AC; Tournoux, A, 1986) |
| "In patients with normal-tension glaucoma (NTG), topical dorzolamide might enhance the vessel density (VD), topical carteolol decreased the VD in the inferior-temporal peripapillary retina, whereas topical brimonidine did not change the VD." | 4.02 | Optical Coherence Tomography Angiography Vessel Density Changes in Normal-tension Glaucoma Treated With Carteolol, Brimonidine, or Dorzolamide. ( Chen, LC; Chuang, LH; Huang, SM; Lin, YH; Su, WW, 2021) |
| "The purpose of the study was to evaluate influence of betaxolol, brimonidine and carteolol in the progression of the visual field defects during time at patients with normotensive glaucoma (NTG)." | 3.96 | Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma. ( Fůs, M; Lešták, J; Marešová, K; Weissová, I, 2020) |
| "We prospectively investigated the efficacy and safety of switching from concomitant latanoprost and carteolol hydrochloride (CH) to a latanoprost/carteolol fixed combination (LCFC) in patients with primary open-angle glaucoma or ocular hypertension." | 3.88 | Short-term Efficacy and Safety of a Latanoprost/Carteolol Fixed Combination Switched From Concomitant Therapy to in Patients With Primary Open-angle Glaucoma or Ocular Hypertension. ( Inoue, K; Ishida, K; Iwasa, M; Shiokawa, M; Tomita, G, 2018) |
| "Patients with primary open angle glaucoma and ocular hypertension were randomized to 62 patients of LA group (LA once a day) and 62 patients of CA group (CA twice a day) in this multicenter, open-label trial." | 2.75 | [Long-acting carteolol hydrochloride 2% ophthalmic solution phase IV study--investigation of the effectiveness, safety and plasma concentration]. ( Ishikawa, Y; Kawase, K; Matsuhisa, A; Migita, M; Muramatsu, T; Nakajima, T; Ono, J; Sugiura, T; Yamamoto, T, 2010) |
| "Carteolol is a commonly-used topical medication for primary open-angle glaucoma." | 1.91 | Carteolol triggers senescence via activation of β-arrestin-ERK-NOX4-ROS pathway in human corneal endothelial cells in vitro. ( Fan, TJ; Jiang, GJ; You, XG, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (20.51) | 18.7374 |
| 1990's | 12 (30.77) | 18.2507 |
| 2000's | 9 (23.08) | 29.6817 |
| 2010's | 4 (10.26) | 24.3611 |
| 2020's | 6 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, GJ | 1 |
| You, XG | 1 |
| Fan, TJ | 1 |
| Lešták, J | 1 |
| Fůs, M | 1 |
| Weissová, I | 1 |
| Marešová, K | 1 |
| Harasymowycz, P | 1 |
| Royer, C | 1 |
| Cui, AX | 1 |
| Barbeau, M | 1 |
| Jobin-Gervais, K | 1 |
| Mathurin, K | 1 |
| Lachaine, J | 1 |
| Beauchemin, C | 1 |
| Lin, YH | 1 |
| Su, WW | 1 |
| Huang, SM | 1 |
| Chuang, LH | 1 |
| Chen, LC | 1 |
| Saito, Y | 1 |
| Kizaki, J | 1 |
| Wada, Y | 1 |
| Shibasaki, Y | 1 |
| Kishimoto, N | 1 |
| Aihara, M | 1 |
| Zafar, A | 1 |
| Alruwaili, NK | 1 |
| Imam, SS | 1 |
| Alsaidan, OA | 1 |
| Alharbi, KS | 1 |
| Yasir, M | 1 |
| Elmowafy, M | 1 |
| Ansari, MJ | 1 |
| Salahuddin, M | 1 |
| Alshehri, S | 1 |
| Inoue, K | 2 |
| Shiokawa, M | 1 |
| Iwasa, M | 1 |
| Ishida, K | 1 |
| Tomita, G | 2 |
| Yamamoto, T | 4 |
| Ikegami, T | 1 |
| Ishikawa, Y | 2 |
| Kikuchi, S | 1 |
| Kawase, K | 1 |
| Muramatsu, T | 1 |
| Ono, J | 1 |
| Nakajima, T | 1 |
| Matsuhisa, A | 1 |
| Sugiura, T | 1 |
| Migita, M | 1 |
| Kawai, M | 1 |
| Nagaoka, T | 1 |
| Takahashi, A | 1 |
| Sato, E | 1 |
| Yoshida, A | 1 |
| Okugawa, K | 1 |
| Kato, S | 1 |
| Inoue, Y | 1 |
| Oshika, T | 1 |
| Amano, S | 1 |
| Renard, P | 1 |
| Kovalski, JL | 1 |
| Cochereau, I | 1 |
| Jaulerry, S | 1 |
| Williamson, W | 1 |
| Elena, PP | 1 |
| Lablache Combier, M | 1 |
| Allaire, C | 2 |
| Siou-Mermet, R | 1 |
| Maruyama, K | 1 |
| Shirato, S | 1 |
| Ikeda, Y | 1 |
| Mori, K | 1 |
| Ishibashi, T | 1 |
| Naruse, S | 1 |
| Nakajima, N | 1 |
| Kinoshita, S | 1 |
| Gorgone, G | 1 |
| Spina, F | 1 |
| Amantia, L | 1 |
| Kitazawa, Y | 2 |
| Azuma, I | 1 |
| Takase, M | 1 |
| Komemushi, S | 1 |
| Ishikawa, T | 1 |
| Okisaka, S | 1 |
| Hiwatari, S | 1 |
| Taketani, P | 1 |
| Sugimachi, Y | 1 |
| Behrens-Baumann, W | 1 |
| Kimmich, F | 1 |
| Walt, JG | 1 |
| Lue, J | 1 |
| Sirbat, D | 1 |
| Charlin, JF | 1 |
| Cohn, H | 1 |
| Dascotte, JC | 1 |
| George, JL | 1 |
| Lesure, P | 1 |
| Massin, M | 1 |
| Massin, G | 1 |
| Maurin, JF | 1 |
| Renard, JP | 1 |
| Noma, A | 1 |
| Maeda, S | 1 |
| Kato, A | 1 |
| Ando, Y | 1 |
| Ido, T | 1 |
| Inazumi, K | 1 |
| Hayakawa, T | 1 |
| Goto, Y | 1 |
| Ichien, M | 1 |
| Diggory, P | 1 |
| Cassels-Brown, A | 1 |
| Fernandez, C | 1 |
| Maeda, H | 1 |
| Tanaka, Y | 1 |
| Yamamoto, M | 1 |
| Mizokami, K | 1 |
| Schmutz, JL | 1 |
| Barbaud, A | 1 |
| Reichert, S | 1 |
| Vasse, JP | 1 |
| Trechot, P | 1 |
| Netland, PA | 1 |
| Weiss, HS | 1 |
| Stewart, WC | 3 |
| Cohen, JS | 2 |
| Nussbaum, LL | 1 |
| Camerino, L | 1 |
| Gastaldi, C | 1 |
| Brogliatti, B | 1 |
| Boles Carenini, B | 1 |
| Osterwalder, P | 1 |
| Garzoli, G | 1 |
| Greminger, P | 1 |
| Dubiner, HB | 1 |
| Mundorf, TK | 1 |
| Laibovitz, RA | 1 |
| Sall, KN | 1 |
| Katz, LJ | 1 |
| Singh, K | 1 |
| Shulman, DG | 1 |
| Siegel, LI | 1 |
| Hudgins, AC | 1 |
| Nussbaum, L | 1 |
| Apostolaros, M | 1 |
| Bartlett, JD | 1 |
| Olivier, M | 1 |
| Richardson, T | 1 |
| Whitaker, R | 1 |
| Pensyl, D | 1 |
| Wilson, MR | 1 |
| Mirza, GE | 1 |
| Karaküçük, S | 1 |
| Temel, E | 1 |
| Quiralte, J | 1 |
| Florido, F | 1 |
| de San Pedro, BS | 1 |
| Demailly, P | 1 |
| Trinquand, C | 1 |
| Watson, PG | 1 |
| Barnett, MF | 1 |
| Parker, V | 1 |
| Haybittle, J | 1 |
| Shields, MB | 1 |
| Allen, RC | 1 |
| Lewis, RA | 1 |
| Hoskins, HD | 1 |
| Hetherington, JN | 1 |
| Bahr, RL | 1 |
| Noblin, JE | 1 |
| Delehanty, JT | 1 |
| Collignon-Brach, J | 1 |
| Pillunat, LE | 1 |
| Stodtmeister, R | 1 |
| Schnaudigel, OE | 1 |
| Becker, H | 1 |
| Fuchs, HB | 1 |
| van Husen, H | 1 |
| Flury, H | 1 |
| Tournoux, A | 1 |
| Martenet, AC | 1 |
1 review available for carteolol and Chronic Primary Open Angle Glaucoma
| Article | Year |
|---|---|
Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis.
Topics: Amides; Antihypertensive Agents; Bayes Theorem; Betaxolol; Bimatoprost; Brimonidine Tartrate; Carteo | 2022 |
23 trials available for carteolol and Chronic Primary Open Angle Glaucoma
| Article | Year |
|---|---|
Comparison of the 24-h efficacy and safety of fixed combination carteolol/latanoprost and timolol/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study.
Topics: Antihypertensive Agents; Carteolol; Cross-Over Studies; Drug Combinations; Glaucoma, Open-Angle; Hum | 2021 |
Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Carteolol; Dos | 2016 |
[Long-acting carteolol hydrochloride 2% ophthalmic solution phase IV study--investigation of the effectiveness, safety and plasma concentration].
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carteolol; Female; Glaucoma, Open-Angle; Humans; Intrao | 2010 |
Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carteolol; Cross-Over Studies; Delayed-Action | 2005 |
Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial.
Topics: Antihypertensive Agents; Carbonic Anhydrase Inhibitors; Carteolol; Cross-Over Studies; Drug Synergis | 2006 |
[Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product].
Topics: Adrenergic beta-Antagonists; Carteolol; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; | 2007 |
Effects of switching from topical beta-blockers to latanoprost on intraocular pressure in patients with normal-tension glaucoma.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Betaxolol; Carteolol; Female; Glaucoma, Open-A | 2008 |
Carteolol: preliminary study on ocular pressure-reducing action.
Topics: Adult; Aged; Carteolol; Clinical Trials as Topic; Female; Glaucoma, Open-Angle; Humans; Intraocular | 1983 |
[Ocular hypotensive effects of carteolol hydrochloride in primary open-angle glaucoma and ocular hypertensive patients. A double-masked cross-over study for the determination of concentrations optimal for the clinical use (author's transl)].
Topics: Carteolol; Clinical Trials as Topic; Double-Blind Method; Glaucoma, Open-Angle; Humans; Intraocular | 1981 |
A comparison of the ocular hypotensive efficacy and systemic safety of 0.5% levobunolol and 2% carteolol.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Carteolol; Child; Double-Blind | 1994 |
[Efficacy and tolerability of 2 presentations of eyedrops combining carteolol 2% and pilocarpine 2% in primary open-angle glaucoma and simple ocular hypertension].
Topics: Adrenergic beta-Antagonists; Aged; Carteolol; Double-Blind Method; Drug Combinations; Female; Glauco | 1995 |
The effects of the beta-adrenergic-blocking agents, timolol and carteolol, on plasma lipids and lipoproteins in Japanese glaucoma patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carteolol; Cholesterol; Cholesterol, HDL; Female; Glaucoma | 1996 |
Topical beta-blockade with intrinsic sympathomimetic activity offers no advantage for the respiratory and cardiovascular function of elderly people.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Airway Resistance; Betaxolol; Blood Pressure; | 1996 |
Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Blood Pressure Mo | 1997 |
Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carteolol; Double-Blind Method; Female; Glauco | 1999 |
Central nervous system and plasma lipid profiles associated with carteolol and timolol in postmenopausal black women.
Topics: Adrenergic beta-Antagonists; Aged; Black People; Brain; Carteolol; Double-Blind Method; Female; Glau | 1999 |
Comparison of the effects of 0.5% timolol maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular pressure and perimetry findings and evaluation of their ocular and systemic effects.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carteolol; Female; Glaucoma, Open-Angle; Humans; Intraocul | 2000 |
Ocular hypotensive efficacy and safety of once daily carteolol alginate.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Alginates; Analysis of Vari | 2001 |
A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma.
Topics: Adrenergic beta-Antagonists; Aged; Betaxolol; Carteolol; Drug Therapy, Combination; Female; Glaucoma | 2001 |
A 3-month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle glaucoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Blood Pressure; Carteolol; Dosage Forms; Do | 1991 |
Early visual field changes with beta-blocking agents.
Topics: Adrenergic beta-Antagonists; Betaxolol; Carteolol; Drug Evaluation, Preclinical; Follow-Up Studies; | 1989 |
[1% carteolol hydrochloride eyedrops: long-term experience in the treatment of chronic open-angle glaucoma].
Topics: Carteolol; Clinical Trials as Topic; Follow-Up Studies; Glaucoma, Open-Angle; Humans; Intraocular Pr | 1986 |
[Tolerance and pharmacologic effectiveness of antiglaucoma eyedrops].
Topics: Adult; Aged; Carteolol; Double-Blind Method; Female; Glaucoma; Glaucoma, Open-Angle; Heart Rate; Hum | 1986 |
15 other studies available for carteolol and Chronic Primary Open Angle Glaucoma
| Article | Year |
|---|---|
Carteolol triggers senescence via activation of β-arrestin-ERK-NOX4-ROS pathway in human corneal endothelial cells in vitro.
Topics: beta-Arrestins; Carteolol; Cellular Senescence; Endothelial Cells; Glaucoma, Open-Angle; Humans; NAD | 2023 |
Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma.
Topics: Betaxolol; Carteolol; Evoked Potentials, Visual; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular | 2020 |
Optical Coherence Tomography Angiography Vessel Density Changes in Normal-tension Glaucoma Treated With Carteolol, Brimonidine, or Dorzolamide.
Topics: Angiography; Brimonidine Tartrate; Carteolol; Female; Fluorescein Angiography; Glaucoma; Glaucoma, O | 2021 |
Formulation of carteolol chitosomes for ocular delivery: formulation optimization,
Topics: Administration, Ophthalmic; Adrenergic beta-Antagonists; Animals; Carteolol; Chitosan; Cornea; Drug | 2021 |
Short-term Efficacy and Safety of a Latanoprost/Carteolol Fixed Combination Switched From Concomitant Therapy to in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Carteolol; Drug Combinations; Drug Substitu | 2018 |
Effects of topical carteolol on retinal arterial blood flow in primary open-angle glaucoma patients.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Fl | 2012 |
Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Carteolol; Dinoprost; Drug Therapy, Combina | 2003 |
[Pilocarpine, carbachol and carteolol on open-angle glaucoma and ocular hypertension (author's transl)].
Topics: Adolescent; Adult; Aged; Carbachol; Carteolol; Female; Glaucoma, Open-Angle; Humans; Intraocular Pre | 1981 |
[Effect of topical carteolol on visual function in normal-tension glaucoma].
Topics: Administration, Topical; Carteolol; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Middle Aged; | 1997 |
First report of sweating associated with topical beta-blocker therapy.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Aged; Carteolol; Glaucoma, Open-Angle; Humans; | 1997 |
Conjunctival vs sublingual administration of carteolol 2% eye drops. Ocular hypotensive effects and some systemic parameter changes.
Topics: Administration, Sublingual; Adrenergic beta-Antagonists; Aged; Carteolol; Chronic Disease; Conjuncti | 1997 |
[Case from general practice. Bradycardic atrial flutter].
Topics: Adrenergic beta-Antagonists; Aged; Atrial Flutter; Bradycardia; Carteolol; Glaucoma, Open-Angle; Hum | 1998 |
Allergic contact dermatitis from carteolol and timolol in eyedrops.
Topics: Adrenergic beta-Antagonists; Carteolol; Cross Reactions; Dermatitis, Allergic Contact; Drug Eruption | 2000 |
Pressure compliance test of the optic nerve head: influence of different antiglaucoma drugs.
Topics: Acetazolamide; Adrenergic beta-Antagonists; Betaxolol; Carteolol; Glaucoma; Glaucoma, Open-Angle; Hu | 1989 |
[Carteolol: general practice-oriented assessment of the effectiveness and tolerance of a new beta-blocker in the treatment of glaucoma].
Topics: Carteolol; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ocular Hypertension; Propanolamines | 1988 |